| December 2021 | American College of Neuropsychopharmacology Poster - "PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor engagement" |
| December 2021 | December 2021 Corporate Presentation |
| October 2021 | European College of Neuropsychopharmacology Poster – "LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies" |
| April 2021 | B. Riley Securities’ Neuroscience Conference Webcast |
| September 2020 | European College of Neuropsychopharmacology Poster – “Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers" [PDF for download] [PDF of AE Chart] |
| May 2020 | Journal of Nuclear Medicine Publication - Real-time LB-102 target engagement using [11C] Raclopride PET |
| September 2019 | European College of Neuropsychopharmacology Poster – “Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic” |
| August 2019 | ACS Omega Publication- Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7
|
| January 2019 | Series A Corporate Presentation |
| October 2018 | European College of Neuropsychopharmacology Poster - "LB-102, Potential Schizophrenia Treatment, Displays Polypharmacology as a Racemate—S Enantiomer Binds D2 Receptors and R Binds 5-HT7Receptor" |
| June 2018 | One Page Corporate Summary |
| May 2018 | Society of Biological Psychiatry Poster - "Establishing a PK-PD-E Relationship for Clinical Candidate LB-102, a Next-Generation Benzamide Antipsychotic" |
| March 2018 | Sachs BioCapital USA Forum - Video of Corporate Presentation |
| March 2018 | Sachs BioCapital USA Forum - Corporate Presentation |
| October 2017 | Additional IP/Patentability Due Diligence
|
| September 2017 | European College of Neuropsychopharmacology Poster - "Pre-clinical Evaluation of Two Novel Benzamides LB-102 and 103 for the Treatment of Schizophrenia" |
